| Identification | Back Directory | [Name]
PIK-294 | [CAS]
900185-02-6 | [Synonyms]
PIK-294
2-((4-Amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-methyl-3-(o-tolyl)q
2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one
2-[[4-Amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-5-methyl-3-(2-methylphenyl)-4(3H)-quinazolinone
4(3H)-Quinazolinone, 2-[[4-aMino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl]Methyl]-5-Methyl-3-(2-Methylphenyl)- | [Molecular Formula]
C28H23N7O2 | [MDL Number]
MFCD17019338 | [MOL File]
900185-02-6.mol | [Molecular Weight]
489.54 |
| Chemical Properties | Back Directory | [Boiling point ]
790.4±70.0 °C(Predicted) | [density ]
1.43 | [storage temp. ]
-20°C | [solubility ]
≥24.5 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH | [form ]
powder | [pka]
8.95±0.10(Predicted) | [color ]
white to beige | [Water Solubility ]
H2O: 10mg/mL, clear
DMSO: 5mg/mL, clear (warmed) | [CAS DataBase Reference]
900185-02-6 |
| Questions And Answer | Back Directory | [Description]
PIK-294 is a highly selective p110δ inhibitor with IC50 of 10 nM, 1000-, 49- and 16-fold less potent to PI3Kα/β/γ, respectively. | [Features]
A p110δ inhibitor. | [In vitro]
PIK-294 shows distinct patterns of isoform selectivity to inhibit different subsets of class I PI3K isoforms (p110β, p110δ, and p110γ) and exhibits low sensitivity to p110α with IC50 of 10 μM). The m-phenol moiety of PIK-294 is able to penetrate the deep-affinity pocket of the ATP binding site, and thus increases in vitro inhibitory activity. |
| Hazard Information | Back Directory | [Uses]
PIK-294 is a derivative of PIK-293 (P437700) and a highly selective inhibitor of p110δ which is an isoform of phosphoinositide 3-kinase (PI3K). | [Biological Activity]
pik-294 is a highly selective p110δ inhibitor, 1000-, 49- and 16-fold less potent to pi3kα/β/γ, respectively.phosphoinositide 3-kinases (pi3-ks) are a key emerging class of drug targets, but the unique roles of pi3-k isoforms remain rarely defined. their target selectivity was biochemically enumerated that revealed cryptic homologies across targets and chemotypes by synthesizing chemically diverse panel of pi3-k inhibitors. crystal structures of three inhibitors to p110g identify a conformationally mobile region that is uniquely exploited by bound selective compounds. this chemical array was then used to define the pi3-k isoforms required for insulin signaling. | [Biochem/physiol Actions]
PIK-294 is a highly selective inihibitor of the phosphoinositide 3-kinase (PI3K) p110δ with an IC50 value of 10 nM compared to IC50 values of 10 μM, 490 nM and 160 nM for PI3Kα/β/γ, respectively. PIK-294 has been used to help distinguish the unique roles of the various PI3-K isoforms. For example, in a study of CXCL8-induced neutrophil migration, PIK-294 inhibited both chemokinetic and chemotactic CXCL8-induced migration whereas PI3Kγ inhibitor AS-605240 markedly reduced CXCL8 induced chemokinetic migration but had no effect on CXCL8 induced chemotactic migration. | [in vivo]
pik-294 bound p110a inhibits the acute effects of insulin treatment in vivo, whereas a p110b inhibitor has no effect. | [IC 50]
10 nm | [storage]
Store at -20°C | [References]
[1] knight za, gonzalez b, feldman me, zunder er, goldenberg dd, williams o, loewith r, stokoe d, balla a, toth b, balla t, weiss wa, williams rl, shokat km, et al. . a pharmacological map of the pi3-k family defines a role for p110alpha in insulin signaling. cell. 2006 may 19;125(4):733-47. epub 2006 apr 27.
[2] bobrovnikova-marjon e1, pytel d, riese mj, vaites lp, singh n, koretzky ga, witze es, diehl ja. perk utilizes intrinsic lipid kinase activity to generate phosphatidic acid, mediate akt activation, and promote adipocyte differentiation. mol cell biol. 2012 jun;32 (12):2268-78. |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
|